Providers Footer Menu

Dr. Ashley Plant, Oncology

Dr. Ashley Plant is a CHOC Children’s specialist in pediatric oncology with a clinical focus in pediatric neuro-oncology and immunotherapy.

Dr. Plant is a member of the neuro-oncology team at CHOC and cares for all types of childhood brain tumors. Her research interests include early clinical trials for brain tumors and immunotherapy. She has a special interest in understanding how the immune system and cancer interact and how this can be exploited for future therapies. She is currently working on bringing a heat shock protein vaccine targeted to specific neo-antigens (or markers) specific to diffuse intrinsic pontine glioma (DIPG) tumors to CHOC.

She has acquired years of experience in the laboratory evaluating the immune cells present in individual brain tumors in an effort to understand how we can use the immune response to kill tumor cells. She was awarded a Young Investigator Award in 2016 by Adaptive Biotechnologies for her work. She has also presented her work at multiple national and international conferences including the 2016 International Symposium on Pediatric Neuro-Oncology in Liverpool, UK.

Dr. Plant is board certified in pediatrics and board eligible for pediatric hematology/oncology. Before joining CHOC Children’s, Dr. Plant attended Stanford School of Medicine. She served her internship and residency at University of California, Los Angeles and completed a pediatric hematology/oncology fellowship at Boston Children’s Hospital/Dana Farber Cancer Institute. Before joining the CHOC team, she was previously a neuro-oncologist at Boston Children’s Hospital/Dana Farber Cancer Institute with an appointment of clinical instructor at Harvard Medical School and there she focused on clinical trial design for pediatric neuro-oncology.

Clinical Interests

Childhood brain tumors and long term survivorship of patients treated for pediatric brain tumors

Research Focus

Early clinical trials for pediatric brain tumors and immunotherapy

Locations:

Outpatient Clinic, Hyundai Cancer Institute at CHOC Children’s
1201 W. La Veta Avenue
Orange, CA  92868

Education:

  • Medical School
    Stanford University School of Medicine, Stanford, CA
  • Pediatrics Residency
    UCLA Ronald Reagan Medical Center, Los Angeles, CA
  • Pediatric Hematology/Oncology Fellowship
    Boston Children’s Hospital, Boston, MA

Administrative Appointments

  • Oncology, CHOC Children’s Specialists

Publications

Weinacht KG, Charbonnier LM, Plant AS, Torgerson TR, Rosenzweig SD, Fleisher TA, Notarangelo AD, Chatila TA. Successful Therapy of a Patient with a Novel STAT1 Gain-of-Function Mutation and Life Threatening Cytopenias with JAX Inhibitor Ruxolitinib. Accepted for publication in Journal of Allergy and Clinical Immunology.

Ramikissoon SH, Bandopadhayay P, Hwang Jaeho, Ramikissoon LA, Greenwald NF, Schumacher S, O’Rourke R, Pinches N, Malkin H, Sinai C, Filbin M, Plant A, Bi WL, Chang M, Yang E, Wright KD, Manley P, Alexandrascu S, Delalle L, Goumnerova L, Church A, Janeway K, Harris M, Folkerth R, Lindeman N, Kieran MW, Ligon AH, Santagata S, Dubuc A, Chi S, Beroukhim R, Ligon KL. Clinical targeted exome-based sequencing in combination with genome wide copy number profiling: A CLIA certified approach for precision medicine in 203 pediatric brain tumors. Accepted in Neuro-Oncology.

Plant A, Chi S, Frazier L. Pediatric Malignant Germ Cell Tumors: a Comparison of the Neuro-Oncology and Solid Tumor Experience. Pediatric Blood and Cancer. 2016. 63: 2086-2095.

Plant A, Venick RS, Farmer DG, Upadhyay S, Said J, Kempert P. Pediatric post transplant lymphoproliferative disorder: a report of two cases of plasmacytoma-like post transplant lymphoproliferative disorder seen in combined liver and intestinal transplant recipients. Pediatric Blood and Cancer. 2013. 60(11): E137-139.

Plant A, Busutil R, Rana A, Nelson S, Auerbach M, Federman N. A single institution study of childhood undifferentiated embryonal liver sarcoma (UELS): success of combined therapy and the use of orthotopic liver transplant. Journal of Clinical Oncology. 2013. 35(6): 451-5.

Lasky J, Panosyna EH, Prins RM, Plant A, Davidson T, Yong WH, Liau LM, Moore TB. Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Pediatric Patients With Newly Diagnosed Or Recurrent High Grade Gliomas. Anticancer Research. 2013. 33(5): 2047-56.

 

Presentations

Plant A, Kieran M, Koyama S, Solomon I, Griffin G, Dranoff G, Ritz J. Immunophenotyping of pediatric brain tumors: Correlating immune infiltrate with histology, mutational load, and survival. International Symposium on Pediatric Neuro-Oncology. Liverpool, UK. June 12-15, 2016

Weinacht KG, Charbonnier LM, Plant AS, Torgerson TR, Rosenzweig SD, Fleisher TA, Notarangelo AD, Chatila TA. Successful Therapy of a Patient with a Novel STAT1 Gain-of-Function Mutation and Life Threatening Cytopenias with JAX Inhibitor Ruxolitinib. American Society of Hematology Annual Meeting. Orlando, FL. December, 2015.

Plant A, Koyama S, Kieran M, Dranoff G, Ritz J. Immunophenotyping of Pediatric Brain Tumors: Does Immune Infiltrate Correlate with Histology. Tumor Immunity Retreat. Boston, MA. November, 2015.

Plant A, Busutil R, Rana A, Nelson S, Auerbach M, Federman N. A single institution study of childhood undifferentiated embryonal liver sarcoma (UELS): success of combined therapy and the use of orthotopic liver transplant. Annual Meeting of American Society of Pediatric Hematology/Oncology. New Orleans, LA. April, 2012.

 

 

 

  • Ashley S Plant MD
    • Appointments:
      714-509-8636
    • Office: 714-509-4348
    • Specialty: Oncology
    • Board Certified: Pediatrics
    • On Staff at: CHOC Children's Hospital

Clinical Trials

HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors

Clinical Trial Protocol # Head Start IV | Brain Tumor/Central Nervous System/Neuro-Oncology | Contact (714) 509-8646

Phase II open-label global study to evaluate the effect of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive relapsed or refractory High Grade Glioma (HGG)

Clinical Trial Protocol # CDRB436G2201 | Adolescents and Young Adults, Brain Tumor/Central Nervous System/Neuro-Oncology, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

Videos

Dr. Ashley Plant

Meet Dr. Ashley Plant

Dr. Ashley Plant is a CHOC Children’s specialist in pediatric oncology with a clinical focus in pediatric neuro-oncology and immunotherapy.

Long Live Childhood

Facebook Twitter Pinterest Instagram Snapchat LinkedIn YouTube